Skip to contentC
Chemed Corp
C
CHEChemed Corp Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$639.34M$639.34Mderived+55.6% vs Q4 2024 Net Income$76.75M$76.75Mderived−15.0% vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Chemed Corp · CIK 19584 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived$100,654,000−11.6% Operating Cash Flowderived$133,533,000−19.0% Free Cash Flowderived$117,185,000−23.0% Margins · derivedOperating margin15.7%−12.0 pt vs Q4 2024
Net margin12.0%−10.0 pt vs Q4 2024
ended Dec 31, 2025 · filed Feb 27, 2026 · 58 d after period end